Harnessing innate and adaptive immunity to fight cancer

Pioneering immune cell engagers

learn more

Our Mission

Our mission at Affimed is to create novel therapeutic options for patients suffering from cancer and other life-threatening diseases through activating innate and adaptive immunity.

With our differentiated approach to arming the body’s innate and adaptive immune systems, we are focused on delivering new treatments beyond the limitations of existing therapies.

learn more about Affimed

Affimed (NASDAQ: AFMD) pioneers immune cell engagement, employing its insights and scientific expertise to harness the body’s innate and adaptive immune systems in the fight against cancer and other life-threatening diseases. Our proprietary ROCK® (Redirected Optimized Cell Killing) platform allows for the modular design of tetravalent bi- and multi-specific antibodies, including first-in-class innate and adaptive cell engager products.

read less

Our Approach

Redirecting immune cells to kill tumor cells

With our differentiated approach to arming the body’s innate and adaptive immune systems, we are focused on delivering new treatments beyond the limitations of existing therapies.
We have used our extensive drug development expertise to generate antibody candidates tailored to different indications, leveraging our proprietary ROCK® platform. ROCK® enables generation of antibodies with the potential for competitive advantages over traditional therapies including highly customizable antibody engagers for tailored treatment options and generation of antibodies with variable pharmacokinetic (PK) profiles.

learn more about our approach

Our Pipeline

Diverse pipeline of differentiated and versatile engagers to activate innate and adaptive immunity

A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.

learn more about our pipeline

NK Cell Engagers

AFM13

Disease Target CD30Immune Cell Target CD16A
Hodgkin lymphoma + PD-1
Phase 1
Hodgkin lymphoma
Phase 2
Hodgkin lymphoma + adoptive NK cells
Pre-IND
CD30-positive lymphoma
Phase 2

AFM24

Disease Target EGFRwtImmune Cell Target CD16A
Solid tumors
Pre-IND

AFM26

Disease Target BCMAImmune Cell Target CD16A
Multiple Myeloma
Pre-IND
Affimed programs
Partnered programs

T Cell Engagers

AFM11

Disease Target CD19Immune Cell Target CD3
Non-Hodgkin lymphoma
Phase 1
Acute lymphocytic leukemia
Phase 1

AMV564 (Amphivena*)

Disease Target CD33Immune Cell Target CD3
Acute myeloid leukemia
Phase 1
Affimed programs
Partnered programs

*AMV564 originates from Affimed’s ROCK® platform.

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.

Okay